RxDoctor Payments Data

Annapoorna Kini, MD

Interventional Cardiology · New York, NYNPI 1952343212

Payments from drug & device makers

What this record shows

This record is dominated by grants: $135,000 of the $176,049 with a category attached, or 76.7%. Boston Scientific accounts for 76.7% of it on its own, with 14 other manufacturers making up the rest. Among interventional cardiology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$176,049in general payments, 2019–2025

Across 92 payments — averaging $1913.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$135K
  • Medtronic$36K
  • Shockwave Medical, Inc$2K
  • Abbott$2K
  • Edwards Lifesciences$252
  • Novartis$113
  • plus $295 from 9 others
$3,304,522in research payments, 2019–2025

Across 209 payments — averaging $15,811 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$2.2M
  • Boston Scientific$418K
  • Abbott$407K
  • Cardiovascular Systems Inc.$119K
  • Shockwave Medical, Inc$98K
  • Medtronic$61K

What the payments were for

  • Consulting fees$2,2001%
  • Speaking & faculty fees$36,00020%
  • Grants$135,00077%
  • Food & beverage$2,8492%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$176,049 in reported general payments places this provider in the 90th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$600,718
Medicare patients
756
Services billed
3,664

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab27$21,076
Praluent PenAlirocumab13$6,628
Prasugrel Hcl21$1,765
ClopidogrelClopidogrel Bisulfate106$1,452
Atorvastatin Calcium48$807
Metoprolol Succinate48$754
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide15$456
Rosuvastatin Calcium20$291
Pantoprazole Sodium33$233
Amlodipine Besylate39$223
Isosorbide Mononitrate ErIsosorbide Mononitrate16$221
Lisinopril13$127
Metoprolol Tartrate21$105
Furosemide17$34
Prednisone22$26

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →